Industry News
Biotechnology Industry News
Hundreds of industry leaders have…
Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were
The FDA is hiring more than 1,000…
The FDA is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs.
No matter who Fierce could pull…
No matter who Fierce could pull aside for a quick coffee at the conference, the general view was of a renewed sense of cautious optimism.
Nurix Therapeutics is trimming its…
Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset.
Contineum Therapeutics’ M1…
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.
Gilead’s general counsel and EVP…
Gilead’s general counsel and EVP of corporate affairs Deborah Telman will hang up the gloves by Dec. 5, the company announced in a brief filing Nov. 15. Gilead didn’t offer any explanation for Telman’s departure,
Moderna, an mRNA specialist known…
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases.
Pfizer has released the full data…
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.
Genetic medicines outfit Ensoma is…
Genetic medicines outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions.
Facing skepticism from analysts…
Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half its workforce to conserve its remaining cash.
Novartis may have signed off on…
Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag.
Aspen Neuroscience’s cash…
Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.
GSK has picked a novel protein…
GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering.
Merck KGaA has become the latest…
Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The German drugmaker has inked a deal to harness Valo’s reams of human biology data to
Stegeman says decentralized trial…
Stegeman says decentralized trial models improve access, diversity and patient retention
After laying off 80% of staffers…
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latter’s CEO on board to helm the company.
Quest Diagnostics emphases the…
Quest Diagnostics emphases the critical role of in vitro diagnostics (IVDs) in shaping modern healthcare and advancing precision medicine.
Korea’s Celltrion is continuing…
Korea’s Celltrion is continuing to move beyond biosmilars, this time securing the option to use TriOar’s antibody platform in a deal potentially worth more than $350 million.
Merck & Co. has reported…
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease.
CEO Paul Stoffels has left, and…
CEO Paul Stoffels has left, and his cell therapy strategy has been scrapped. So what happened to Galapagos?